ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for
VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc. This trial is to evaluate its safety, tolerability,
pharmacokinetic, and efficacy in patients with advanced renal cell carcinoma (RCC).
In phase Ib, the primary objectives are to assess the safety and tolerability, and to
determine the maximum tolerated dose (MTD) of ST-1898 tablets in patients with advanced RCC.
Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the
efficacy in patients with advanced RCC.
In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets
in patients with advanced RCC. The secondary objective is to evaluate the safety of ST-1898
tablets in patients with advanced RCC.